Diabetes and Hypertension: Pathogenesis, Prevention and Treatment

References

• Jandeleit‐Dahm K, Cooper M E. Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002; 11: 221–228, [CSA]
   Google Scholar
• Phillips C A, Molitch M E. The relationship between glucose control and the development and progression of diabetic nephropathy. Curr. Diabetes Rep. 2002; 2: 523–529, [CSA]
   Google Scholar
• Lurbe E, Redon J, Kesani A, Pascual J M, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797–805, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Bujalska I J, Walker E A, Hewison M, Stewart P M. A switch in dehydrogenase to reductase activity of 11 beta‐hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002; 87: 1205–1210, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Giacchetti G, Faloia E, Sardu C, Camilloni M A, Mariniello B, Gatti C, Garrapa G GM, Guerrieri M, Mantero F. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes 2000; 24: S142–S143, [CROSSREF]
   Google Scholar
• Daly P A, Landsberg L. Pathogenesis of hypertension in NIDDM: lessons from obesity. J Hum Hypertens 1991; 5: 277–285, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Zanchetti A, Ruilope L M. Antihypertensive treatment in patients with type‐2 diabetes mellitus; what guidance from recent controlled randomized trials?. J Hypertens 2002; 20: 2099–2110, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes G T, Mallion J M, Ruilope L, Wedel H. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 2001; 19: 1149–1159, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Tuomilehto J, Borch‐Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, Reunanen A. Incidence of cardiovascular disease in Type 1 (insulin‐dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784–790, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Dinneen S F, Gerstein H C. The association of microalbuminuria and mortality in non‐insulin‐dependent diabetes mellitus. Arch Intern Med 1997; 157: 1413–1418, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo J L, Jr, Jones D W, Materson B J, Oparil S, Wright J T, Jr, Roccella E J, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560–2572, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Ritz E, Rychlik I, Locatelli F, Halimi S. End‐stage renal failure in Type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795–808, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403, [CROSSREF]
   Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne‐Parikka P, Keinanen‐Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Aunola S, Cepaitis Z, Moltchanov V, Hakumaki M, Mannelin M, Martikkala V, Sundvall J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Pan X R, Li G W, Hu Y H, Wang J X, Yang W Y, An Z X, Hu Z X, Lin J, Xiao J Z, Cao H B, Liu P A, Jiang X G, Jiang Y Y, Wang J P, Zheng H, Zhang H, Bennett P H, Howard B V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537–544, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Buchanan T, Xiang A H, Peters R K, Kjos S L, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis H N, Azen S P. Preservation of pancreatic [beta]‐cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high‐risk hispanic women. Diabetes 2002; 51: 2796–2803, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Gæde P, Vedel P, Larsen N, Jensen G VH, Parving H H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393, [CROSSREF]
   Google Scholar
• Arauz‐Pacheco C, Parrott M A, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199–201, [CSA]
   Google Scholar
• Bakris G L, Williams M, Dworkin L, Elliott W J, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661, [PUBMED], [INFOTRIEVE]
   Google Scholar
• The Hope Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO_HOPE substudy. Lancet 2000; 355: 253–259, [CROSSREF]
   Google Scholar
• Lindholm L H, Ibsen H, Dahlof B, Devereux R B, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen S E, Kristiansson K, Lederballe‐Pedersen O, Nieminen M S, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel B HR, Zinman for the HOPE Study Investigators B. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–1885, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Lindholm L H, Ibsen H, Borch‐Johnsen K, Olsen M H, Wachtell K, Dahlöf B, Devereux R B, Beevers G, de Faire U, Fyhrquist F, Julius S, Kristianson K, Lederballe‐Pedersen O, Nieminen M S, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J M, Snapinn S. Risk of new‐onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–1886, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• ALLHAT Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–2997, [CROSSREF]
   Google Scholar
• Snow V, Weiss K B, Mottur‐Pilson C, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587–592, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Vijan S, Hayward R A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593–602, [PUBMED], [INFOTRIEVE]
   Google Scholar